TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03396575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
Description: Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Intensified TMZ
Description: After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td vaccine
Description: A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td vaccine
Description: A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cells (HSC)
Description: During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cells (HSC)
Description: During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
Study: NCT05051345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on the services provided for pregnant women and smoking cessation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive tobacco cessation self-help materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive Smoke-Free Homes mailings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Download and use the Wellness app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Download and use the Wellness app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01863550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT05051345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01799954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AIDSVAX® B/E
Description: 300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AIDSVAX® B/E
Description: 300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
Study: NCT05051345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive Smoke-Free Homes kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive a coaching call from a Baby Steps for Health counselor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive telephone counseling sessions
Study: NCT05051345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive telephone counseling sessions
Study: NCT04019327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8
Study: NCT03753074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
Study: NCT01863550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01799954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AIDSVAX® B/E
Description: 300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for DNA/NYVAC
Description: Sodium Chloride for injection, 0.9% administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for DNA/NYVAC
Description: Sodium Chloride for injection, 0.9% administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for DNA/NYVAC
Description: Sodium Chloride for injection, 0.9% administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for DNA/NYVAC
Description: Sodium Chloride for injection, 0.9% administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for AIDSVAX(R) B/E
Description: 600 mcg of aluminum hydroxide adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for AIDSVAX(R) B/E
Description: 600 mcg of aluminum hydroxide adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for AIDSVAX(R) B/E
Description: 600 mcg of aluminum hydroxide adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for AIDSVAX(R) B/E
Description: 600 mcg of aluminum hydroxide adjuvant, administered IM
Study: NCT03176134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV solution or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV solution or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV solution or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV solution or oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
Study: NCT03722303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat Injection
Description: Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Injection
Description: Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
Study: NCT01468688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 combination therapy
Study: NCT03993080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality relaxation
Description: 1-3.5 minute 360° videos
Study: NCT02500615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
Study: NCT01546363

Intervention type: OTHER
Intervention: Blood draw
Description: phlebotomy

Intervention type: OTHER
Intervention: Blood draw
Description: phlebotomy
Study: NCT05228717

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Ultrasound
Description: q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
Study: NCT04224662

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT00841620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemorrhoidectomy a.m. Milligan
Description: Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled anopexy
Description: Surgery
Study: NCT01863550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03786614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuation of serotonergic antidepressants
Description: Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of serotonergic medications
Description: Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
Study: NCT03039972

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT04063098

Intervention type: OTHER
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
Study: NCT04528173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
Study: NCT02812407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Impedance
Description: During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm
Study: NCT00739453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally
Study: NCT03258177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
Study: NCT03194503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VL Coaching training using C-MAC video laryngoscope
Description: Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card).
Study: NCT03491943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-assisted midline approach
Description: A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-assisted paramedian approach
Description: A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
Study: NCT00457366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cogentin
Description: given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
Study: NCT00844818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Quitline Enrollment
Description: The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
Study: NCT02894632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI compatible motion sensor (MARMOT)
Description: MRI with motion control (several motion sensors placed on the volunteer's body)
Study: NCT04589468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
Study: NCT04139902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab (TSR-042) (singly)
Description: If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks.
Study: NCT04163146

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurements of PEF and FEV1
Description: Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurements of PEF and FEV1
Description: Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
Study: NCT03360981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretins
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.